Blood Res.  2021 Sep;56(3):202-204. 10.5045/br.2021.2021067.

Romiplostim plus danazol as salvage treatment for eltrombopag refractory immune thrombocytopenia: a retrospective pilot study

• Nam CH
• Byun JM
• Shin DY
• Hong J
• Kim I
• Yoon SS
• Koh Y

• KMID: 2520615
• DOI: http://doi.org/10.5045/br.2021.2021067

Abstract

No abstract available

Figure

• 

  Fig. 1 Mean (±standard error of the mean) platelet count changes during follow-up.

Reference

1. Kuter DJ. 2013; The biology of thrombopoietin and thrombopoietin receptor agonists. Int J Hematol. 98:10–23. DOI: 10.1007/s12185-013-1382-0. PMID: 23821332.

2. Neunert CE, Cooper N. 2018; Evidence-based management of immune thrombocytopenia: ASH guideline update. Hematology Am Soc Hematol Educ Program. 2018:568–75. DOI: 10.1182/asheducation-2018.1.568. PMID: 30504359. PMCID: PMC6245979.

3. Rodeghiero F, Stasi R, Gernsheimer T, et al. 2009; Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 113:2386–93. DOI: 10.1182/blood-2008-07-162503. PMID: 19005182.

4. Rodeghiero F, Ruggeri M. 2015; Treatment of immune thrombocytopenia in adults: the role of thrombopoietin-receptor agonists. Semin Hematol. 52:16–24. DOI: 10.1053/j.seminhematol.2014.10.006. PMID: 25578415.

5. Cooper N, Bussel J. 2006; The pathogenesis of immune thrombocytopaenic purpura. Br J Haematol. 133:364–74. DOI: 10.1111/j.1365-2141.2006.06024.x. PMID: 16643442.

6. Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL. 2009; Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood. 113:2161–71. DOI: 10.1182/blood-2008-04-150078. PMID: 18981291.

7. Bussel JB, Provan D, Shamsi T, et al. 2009; Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet. 373:641–8. DOI: 10.1016/S0140-6736(09)60402-5. PMID: 19231632.

8. González KJ, Zuluaga SO, DaRos CV, Rodríguez PP, Martí AC. 2017; Sequential treatment with thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): experience in our center. Ann Hematol. 96:507–8. DOI: 10.1007/s00277-016-2896-3. PMID: 27975127.

9. Lakhwani S, Perera M, Fernández-Fuertes F, et al. 2017; Throm-bopoietin receptor agonist switch in adult primary immune thrombocytopenia patients: a retrospective collaborative survey involving 4 Spanish centres. Eur J Haematol. 99:372–7. DOI: 10.1111/ejh.12932. PMID: 28759125.

10. Kuter DJ, Macahilig C, Grotzinger KM, et al. 2015; Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim. Int J Hematol. 101:255–63. DOI: 10.1007/s12185-014-1731-7. PMID: 25586660.

11. Khellaf M, Viallard JF, Hamidou M, et al. 2013; A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia. Haematologica. 98:881–7. DOI: 10.3324/haematol.2012.074633. PMID: 23445876. PMCID: PMC3669443.

12. Tsukamoto S, Nakaseko C, Takeuchi M, et al. 2013; Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia. Br J Haematol. 163:286–9. DOI: 10.1111/bjh.12483. PMID: 23862773.

13. Neunert C, Terrell DR, Arnold DM, et al. 2019; American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 3:3829–66. DOI: 10.1182/bloodadvances.2019000966. PMID: 31794604. PMCID: PMC6963252.

14. Ahn YS, Harrington WJ, Simon SR, Mylvaganam R, Pall LM, So AG. 1983; Danazol for the treatment of idiopathic thrombocytopenic purpura. N Engl J Med. 308:1396–9. DOI: 10.1056/NEJM198306093082306. PMID: 6682484.